Search
Search Results
-
Efficacy of transcutaneous electrical nerve stimulation combined with mirabegron therapy compared with mirabegron monotherapy for overactive bladder: a prospective randomized controlled study
PurposeThe objective was to evaluate the efficacy of transcutaneous electrical nerve stimulation (TENS) combined with mirabegron therapy compared...
-
Relief of double-J stent-related symptoms: a comparison between mirabegron, tamsulosin and solifenacin
BackgroundInserting ureteral stents is a routine intervention that often results in problems. The cornerstone for treating stent-related symptoms is...
-
Treatment Patterns with Mirabegron and Antimuscarinics for Overactive Bladder: A Prospective, Registry Study in Taiwan and South Korea (FAITH)
IntroductionThis study aimed to assess overactive bladder (OAB) treatment patterns and factors associated with effectiveness and persistence.
...
-
Assessment of Codispensing Patterns of Mirabegron and Prespecified CYP2D6 Substrates in Patients with Overactive Bladder
BackgroundPatients with overactive bladder (OAB) experience sudden, intense urges to urinate, which may include urge urinary incontinence and...
-
Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial
PurposeTo compare the efficacy and safety of mirabegron and vibegron in female OAB patients.
MethodsWe conducted a multicenter, prospective,...
-
Nerve Growth Factor and Brain-Derived Neurotrophic Factor as Potential Biomarkers of Mirabegron Efficacy in Patients with Overactive Bladder Syndrome
IntroductionOveractive Bladder Syndrome (OAB) significantly impacts quality of life, necessitating improved diagnostic tools and treatment...
-
CYP2D6 Substrate Dispensing Among Patients Dispensed Mirabegron: An Administrative Claims Analysis
BackgroundOveractive bladder (OAB) is characterized by the presence of bothersome urinary symptoms. Pharmacologic treatment options for OAB include...
-
Evaluation of the efficacy and safety of either or both mirabegron and silodosin, as a medical expulsive therapy for distal ureteric stones
ObjectiveTo evaluate efficacy and safety of either or both silodosin and mirabegron as MET for distal ureteric stones ≤ 10 mm.
Patients and methods ...
-
Mirabegron vs. solifenacin in control of endoscopically inserted ureteral stent-related symptoms
PurposeWe aimed to assess the efficacy and safety of Mirabegron vs. solifenacin to treat LUTS resulting from DJ-stent insertion.
Methods ...
-
Does metabolic syndrome influence the efficacy of mirabegron treatment in female patients with overactive bladder?
Introduction and hypothesisWe aimed to determine whether the presence of metabolic syndrome (MS) affects the efficacy of mirabegron in...
-
Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study)
BackgroundWe assessed the efficacy and safety of mirabegron, a β 3 -adrenoceptor agonist, in older adults (≥ 80 years old) with overactive bladder...
-
Symptom improvement with mirabegron treatment is associated with urobiome changes in adult women
Introduction and hypothesisMirabegron, a beta-3 agonist, is prescribed for urgency urinary incontinence (UUI). We assessed the correlation of symptom...
-
Mirabegron: Pediatric First Approval
Mirabegron (MYRBETRIQ ® ), a beta-3 adrenergic agonist developed by Astellas Pharma Inc., is well established as a treatment for overactive bladder in...
-
Comparative effectiveness of pelvic floor muscle training, mirabegron, and trospium among older women with urgency urinary incontinence and high fall risk: a feasibility randomized clinical study
BackgroundUntreated, urgency urinary incontinence (UUI) and overactive bladder (OAB) can precipitate a vicious cycle of decreasing physical activity,...
-
Safety and short-term efficacy of mirabegron in children with valve bladder: a pilot study
AimsThis pilot study aims to assess the short-term efficacy and safety of mirabegron in valve bladder, an important cause of persistent...
-
Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison
BackgroundIn the absence of head-to-head trials, we performed an indirect treatment comparison of the β 3 -adrenergic agonists vibegron and mirabegron...
-
Mirabegron improves erectile function in men with overactive bladder and erectile dysfunction: a 12-week pilot study
Phosphodiesterase type 5 inhibitors (PDE5i) is the only approved oral treatment for erectile dysfunction (ED) in the US, and alternative management...
